| 摘要 |
<p>The present invention is directed to a method of slowing the rate of progression of the myocardial structural damages in a human subject having CHF, comprising administering to said subject a safe and effective amount of a 14-aminosteroid compound or acid salt thereof of general formula (I) wherein a) R1 is (i) COOR5, where R5 is a lower alkyl group containing 1 to 4 carbon atoms, a lower alkyl group containing 2 to 4 carbon atoms substituted by an amino group, or an arylalkyl group containing 6 to 12 carbon atoms, or (ii) CHR6OH, where R6 is a hydrogen atom or lower alkyl group containing 1 to 4 carbon atoms; b) R2 is -NR7R8, where R7 and R8, which may be the same or different, are hydrogen atoms or lower alkyl group containing 1 to 4 carbon atoms; c) R3 is (i) monosaccharide sugar residue, wherein (II) R9 is a hydrogen atom, a hydroxy group, or an acetoxy group, R10 is a hydroxy or acetoxy group, or R9 and R10 together form a divalent alkylenedioxy group, R11 represents a hydroxy group, a methoxy group, or an acetoxy group, and R12 is a methyl group or a hydroxy-methyl group, or (ii) OH; d) R4 is (i) OH, or (ii) H, or (iii) OR13, where R13 is said monosaccharide sugar residue; e) Z is (i) -CH-, where a and b are single bonds, or (ii) =C, where either a or b is a double bond. The 14-aminosteroid is preferably administered in a pharmaceutical composition comprising the 14-aminosteroid and a pharmaceutically acceptable carrier.</p> |
